Clinical data
| . | All with diabetes . | Impaired awareness . | Normal awareness . |
|---|---|---|---|
| Total NSS score, median (IQR) | 1.0 (3.0) | 1 (3.0) | 1 (3.0) |
| Neuropathic pain, n (%) | |||
| No | 51 (77.3) | 24 (72.2) | 27 (81.8) |
| Possible | 3 (4.5) | 1 (3) | 2 (6.1) |
| Yes | 12 (18.2) | 8 (24.2) | 4 (12.1) |
| Total NIS sum, median (IQR) | 10 (12.0) | 10 (12.5) | 10 (11.0) |
| Staged evaluation of DSPN,* n (%) | |||
| Stage 0 | 14 (21.1) | 6 (18.2) | 8 (24.2) |
| Stage 1a | 16 (24.2) | 8 (24.2) | 8 (24.2) |
| Stage 1b | 17 (25.8) | 9 (27.3) | 8 (24.2) |
| Stage 2a | 19 (28.8) | 10 (30.3) | 9 (27.3) |
| SAS | |||
| Symptoms reported, n | 1.0 (2.0) | 2.0 (2.0) | 1.0 (1.5) |
| Total impact score, median (IQR) | 3.0 (5.0) | 3.5 (4.0) | 2.5 (5.0) |
| . | All with diabetes . | Impaired awareness . | Normal awareness . |
|---|---|---|---|
| Total NSS score, median (IQR) | 1.0 (3.0) | 1 (3.0) | 1 (3.0) |
| Neuropathic pain, n (%) | |||
| No | 51 (77.3) | 24 (72.2) | 27 (81.8) |
| Possible | 3 (4.5) | 1 (3) | 2 (6.1) |
| Yes | 12 (18.2) | 8 (24.2) | 4 (12.1) |
| Total NIS sum, median (IQR) | 10 (12.0) | 10 (12.5) | 10 (11.0) |
| Staged evaluation of DSPN,* n (%) | |||
| Stage 0 | 14 (21.1) | 6 (18.2) | 8 (24.2) |
| Stage 1a | 16 (24.2) | 8 (24.2) | 8 (24.2) |
| Stage 1b | 17 (25.8) | 9 (27.3) | 8 (24.2) |
| Stage 2a | 19 (28.8) | 10 (30.3) | 9 (27.3) |
| SAS | |||
| Symptoms reported, n | 1.0 (2.0) | 2.0 (2.0) | 1.0 (1.5) |
| Total impact score, median (IQR) | 3.0 (5.0) | 3.5 (4.0) | 2.5 (5.0) |
*Diabetic sensorimotor neuropathy graded according to the Toronto Consensus Panel on Diabetic Neuropathy.
IQR, interquartile range.